Unknown

Dataset Information

0

Toll-Like Receptor-4 Disruption Suppresses Adipose Tissue Remodeling and Increases Survival in Cancer Cachexia Syndrome.


ABSTRACT: Cancer-induced cachexia, characterized by systemic inflammation, body weight loss, adipose tissue (AT) remodeling and muscle wasting, is a malignant metabolic syndrome with undefined etiology. Here, we show that both genetic ablation and pharmacological inhibition of TLR4 were able to attenuate the main clinical markers of cachexia in mice bearing Lewis lung carcinoma (LLC). AT remodelling was not found in LLC tumor-bearing (TB) TLR4-/- mice due to reduced macrophage infiltration and adipocyte atrophy. TLR4-/- mice were also resistant to cold-induced browning of subcutaneous AT (scAT). Importantly, pharmacological inhibition of TLR4 (Atorvastatin) reproduced the main protective effect against AT remodeling found in TLR4-/- TB mice. Moreover, the treatment was effective in prolonging survival and attenuating tumor mass growth when compared to non-treated-TB animals. Furthermore, tumor-induced elevation of circulating pro-inflammatory cytokines was similarly abolished in both genetic ablation and pharmacological inhibition of TLR4. These data suggest that TLR4 is a critical mediator and a promising target for novel anti-cachexia therapies.

SUBMITTER: Henriques F 

PROVIDER: S-EPMC6303407 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Toll-Like Receptor-4 Disruption Suppresses Adipose Tissue Remodeling and Increases Survival in Cancer Cachexia Syndrome.

Henriques Felipe F   Lopes Magno A MA   Franco Felipe O FO   Knobl Pamela P   Santos Kaltinaitis B KB   Bueno Luana L LL   Correa Victor A VA   Bedard Alexander H AH   Guilherme Adilson A   Birbrair Alexander A   Peres Sidney B SB   Farmer Stephen R SR   Batista Miguel L ML  

Scientific reports 20181221 1


Cancer-induced cachexia, characterized by systemic inflammation, body weight loss, adipose tissue (AT) remodeling and muscle wasting, is a malignant metabolic syndrome with undefined etiology. Here, we show that both genetic ablation and pharmacological inhibition of TLR4 were able to attenuate the main clinical markers of cachexia in mice bearing Lewis lung carcinoma (LLC). AT remodelling was not found in LLC tumor-bearing (TB) TLR4<sup>-/-</sup> mice due to reduced macrophage infiltration and  ...[more]

Similar Datasets

| S-EPMC8803848 | biostudies-literature
2024-07-16 | GSE235304 | GEO
| S-EPMC2869165 | biostudies-literature
| S-EPMC6818538 | biostudies-literature
| S-EPMC3965507 | biostudies-literature
| S-EPMC9563866 | biostudies-literature
| S-EPMC8495409 | biostudies-literature
| S-EPMC5465966 | biostudies-other
2024-07-16 | GSE235302 | GEO
2024-07-16 | GSE234884 | GEO